Latest Current Report
Filed: 2026-04-21
Key Insights
- Chief Financial Officer Nathan Jorgensen is departing effective May 8, 2026, to pursue a new opportunity with no disagreement with the company, indicating a planned transition rather than a forced departure.
- Robin Swartz, currently Chief Operating Officer and Chief Business Officer, is being promoted to principal financial officer and treasurer, leveraging her extensive finance background including over 10 years in finance roles at Sanofi Genzyme and recent CFO experience at Voyager (April-July 2024).
- Amy Quinlan, Vice President of Finance since January 2025, is being elevated to principal accounting officer, bringing relevant controller and financial accounting experience from prior roles at Vor Biopharma and Tetraphase Pharmaceuticals.
- The succession plan demonstrates internal depth and continuity, as both replacements are already embedded in the organization with recent experience in their new roles, minimizing external search costs and operational disruption.